EVAX

Investor Moves

Investor	Portfolio Value	Portfolio Change	Position Change	Avg Buy Price	Current Price
Steven CohenPoint72 $-157.9K ExitQ1 2026 $158k -- $4.06

News

globenewswire.comEvaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congressglobenewswire.comMay 12

seekingalpha.comEvaxion A/S (EVAX) Q1 2026 Earnings Call Transcriptseekingalpha.comMay 7

globenewswire.comEvaxion announces business update and first quarter 2026 financial resultsglobenewswire.comMay 7

globenewswire.comEvaxion to announce business update and first quarter 2026 financial results on May 7, 2026globenewswire.comMay 4

globenewswire.comEvaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officerglobenewswire.comApr 27

Trade EVAX

About Evaxion Biotech A/S

Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.

CEO: Helen Katrina Tayton-Martin
IPO Date: Feb 5, 2021

Market Data

Market data refresh is queued when this stock page is viewed.

Valuation

Valuation snapshot is not available yet.

Financials

Financial statement snapshot is not available yet.

Events

EarningsAug 13

EPS est. -0.01